BD (NYSE: BDX) announced plans to eliminate 60 positions at its manufacturing facility based in Drogheda, Ireland. A statement provided by a BD spokesperson confirmed a targeted reduction of 60 positions due to a combination of factors. These include the effects of the COVID-19 pandemic and the company’s spinoff of its diabetes business, Embecta. The […]
BD
BD continues to expand in Ireland
BD (NYSE:BDX) announced that it opened a new facility in Ireland and committed a further investment within the country. Last week, the company held a grand opening ceremony for a new $4.3 million (€4 million) R&D facility in Blackrock, Dublin. BD also announced an additional $32.1 million (€30 million) investment to expand its Enniscorthy, Wexford […]
BD expands availability of all-in-one flush pre-filled syringe
BD (NYSE:BDX) announced today that it expanded customer availability for its all-in-one pre-filled flush syringe. Franklin Lakes, New Jersey-based BD designed its PosiFlush SafeScrub syringe with an integrated disinfection unit. It reinforces compliance with infection prevention guidelines, simplifying nursing workflow. BD built the active disinfection unit right into the tip cap of the PosiFlush SafeScrub […]
Embecta stock rises on Q2 results, reports progress on automated insulin delivery tech
Embecta (Nasdaq:EMBC) shares ticked up today on second-quarter results that topped the consensus forecast, leading to a guidance increase. Shares of EMBC grew 2.1% to $29.52 apiece in early-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose 0.1%. The Parsippany, New Jersey-based diabetes technology […]
BD unveils ultrasound tech for IV insertions
BD (NYSE:BDX) announced today that it launched a new ultrasound device to help clinicians achieve optimal IV placement. The new, easy-to-use, advanced ultrasound device — called the Prevue II — features a special probe. BD designed the Prevue II to address an unmet need in IV access through real-time needle depth markers. Franklin Lakes, New […]
BD issues vulnerability warning for Alaris infusion monitoring software
BD (NYSE:BDX) today issued a voluntary notification regarding cybersecurity vulnerabilities with its Alaris Infusion Central software. Alaris Infusion Central, a standalone software — separate from pumps — provides data from the Alaris pumps. It allows healthcare providers to monitor infusion data sent from Alaris Plus and Alaris neXus pumps on a computer. Alaris Infusion Central […]
How Embecta started strong and what’s ahead for the BD diabetes spinoff
Ten months after spinning off from BD, Embecta CEO Dev Kurdikar lays out what the future holds for the diabetes technology company. When Embecta became a standalone company in April 2022, CFO Jake Elguicze said he felt it was “uniquely positioned.” As a pure-play diabetes technology developer, its beginning phase hardly mirrors a normal startup. […]
The 10 biggest diabetes tech stories from 2022
2022 represented a landmark year for next-generation diabetes tech. Here are the biggest stories from the past year. Some companies picked up major regulatory nods. Others experienced major regulatory setbacks. Partnerships were formed and ended, while mergers and acquisitions came and went. There were many stories to choose from in the world of diabetes tech, […]
Embecta stock slides on mixed Q4 results
Embecta (Nasdaq:EMBC) shares dipped today on fourth-quarter results that came in mixed compared to the consensus forecast. EEMBC shares fell more than 12% to $29.73 apiece in morning trading. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was up more than 4%. The Parsippany, New Jersey-based company posted losses […]
Analysts remain neutral on Embecta, await insulin patch pump developments
BTIG analysts maintained their neutral rating for Embecta (Nasdaq:EMBC) ahead of the company’s fourth-quarter earnings report next week. Embecta, the BD diabetes spinoff, reports its fourth-quarter earnings on Tuesday, Dec. 20. Analysts Marie Thibault and Sam Eiber also expect 2023 guidance to come from management then. The analysts mainly expect the patch pump market to […]
